OOOliver G. Opitz

Oliver G. Opitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oliver G. Opitz has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Zielgerichtete Therapie gastrointestinaler Tumoren

    by S. Heeg, G. Illerhaus, O.G. Opitz

  • Open Access

    CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients

    by J Harder, V Engelstaedter, H Usadel, S Lassmann, M Werner, P Baier, F Otto, M Varbanova, E Schaeffner, M Olschewski, et al.

    Patients with UICC stage II colorectal cancer (CRC) have a risk of approximately 20% to develop disease recurrence after tumour resection. The presence and significance of micrometastases for locoregional recurrence in these patients lacking histopathological lymph node involvement on routine stained HE sections is undefined. Oestrogen receptor (ER) promoter methylation has earlier been identified in CRC. Therefore, we evaluated the methylation status of the ER promoter in lymph nodes from 49 patients with CRC UICC stage I and II as a molecular marker of micrometastases and predictor of local recurrence. DNA from 574 paraffin-embedded lymph nodes was isolated and treated with bisulphite. For the detection of methylated ER promoter sequences, quantitative real-time methylation-specific PCR was used. Of the 49 patients tested, 15 (31%) had ER methylation-positive lymph nodes. Thirteen of those (86%) remained disease free and two (14%) developed local recurrence. In the resected lymph nodes of 34 of the 49 patients (69%), no ER promoter methylation could be detected and none of these patients experienced a local relapse. The methylation status of the ER promoter in lymph nodes of UICC stage I and II CRC patients may be a useful marker for the identification of patients at a high risk for local recurrence.


  • Open Access

    Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver

    by Jan Harder, Oliver G. Opitz, Jan Brabender, Manfred Olschewski, Hubert E. Blum, Shuji Nomoto, Henning Usadel

    Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Little is known about its molecular pathogenesis and the relevance of DNA methylation for disease initiation and progression. Nevertheless, promoter methylation of some genes has been implicated as potential marker for HCC. Thirty‐four HCC, 34 matching non‐malignant, cirrhotic livers and 16 normal livers were analyzed for the methylation status of the genes p16INK4a, GSTP1, MGMT, DAP‐K and APC by quantitative methylation‐specific PCR. DNA promoter methylation frequencies in HCC and matching non‐malignant cirrhotic liver, respectively, were as follows: p16INK4a (76% vs. 24%), GSTP1 (53% vs. 32%), MGMT (6 vs. 12%), DAP‐K (68 vs. 100%) and APC (100 vs. 100%). GSTP1 and/or p16INK4a promoter methylation was observed in 88% of the HCC samples. In normal liver tissue, the p16INK4a, GSTP1 and MGMT promoter were not methylated. DAP‐K was methylated in 31% and APC even in 100% of normal liver samples. Quantitative levels of methylated promoter DNA of all genes were significantly different in the various tissue types except for MGMT. Our results suggest that promoter methylation of tumor‐associated genes is a common event in hepatocarcinogenesis. Significantly, higher levels and frequencies of promoter methylation in HCC were found for p16INK4a and GSTP1 compared to non‐malignant cirrhotic liver. This indicates that these epigenetic events may serve as a good marker for HCC. These data also demonstrate the importance of the quantification of methylated promoter DNA within a given sample and the use of normal tissue as controls. Quantitative analyses of methylated GSTP1 and p16INK4a promoter may serve as a powerful molecular marker in detecting HCC in biopsies.